Literature DB >> 22180175

KIR/HLA combination associated with the risk of complications in celiac disease.

Laura Caggiari1, Giuseppe Toffoli, Valli De Re, Nicoletta Orzes, Michele Spina, Mariangela De Zorzi, Stefania Maiero, Renato Cannizzaro, Vincenzo Canzonieri.   

Abstract

The pathogenesis of celiac disease (CD) is associated with polymorphisms in human leukocyte antigen (HLA) genes; however, compelling evidence suggests that additional non-HLA genes are associated with CD and related complications. The present study investigated whether killer cell immunoglobulin-like receptor (KIR)/HLA gene combinations are associated with CD and its clinical complications in the population of northeast Italy. The study included 61 adults affected by CD: 48 patients were at first diagnosis and 13 patients had CD-related complications (8 with refractory CD and 5 with cancer). Controls were 69 blood donors genotyped for KIR and HLA. Several statistically significant differences emerged between CD patients and blood donors. The results herein presented show that susceptibility to CD with refractory disease or cancer is associated with various genotypes including the 2DS2/2DL2+C1, 2DS3, 3DL1, and 2DL5B genes. In addition, the absence of the Bw4 ligand may be a predisposing factor for cancer. These results suggest that a KIR haplotype and HLA ligands may be involved in the susceptibility to important clinical CD complications such as tumors or refractoriness as a result of a gluten-free diet.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22180175     DOI: 10.5301/JBM.2011.8903

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   2.659


  6 in total

1.  Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases.

Authors:  Valli De Re; Laura Caggiari; Mariangela De Zorzi; Ombretta Repetto; Anna Linda Zignego; Francesco Izzo; Maria Lina Tornesello; Franco Maria Buonaguro; Alessandra Mangia; Domenico Sansonno; Vito Racanelli; Salvatore De Vita; Pietro Pioltelli; Emanuela Vaccher; Massimiliano Berretta; Massimiliano Beretta; Cesare Mazzaro; Massimo Libra; Andrea Gini; Antonella Zucchetto; Renato Cannizzaro; Paolo De Paoli
Journal:  PLoS One       Date:  2015-02-20       Impact factor: 3.240

2.  Influence of HLA class I, HLA class II and KIRs on vertical transmission and chronicity of hepatitis C virus in children.

Authors:  A Ruiz-Extremera; E J Pavón-Castillero; M Florido; P Muñoz de Rueda; J A Muñoz-Gámez; J Casado; A Carazo; R Quiles; S M Jiménez-Ruiz; A Gila; J D Luna; J León; J Salmerón
Journal:  PLoS One       Date:  2017-02-22       Impact factor: 3.240

3.  KIR-HLA Functional Repertoire Influences Trastuzumab Efficiency in Patients With HER2-Positive Breast Cancer.

Authors:  Elena Muraro; Mariangela De Zorzi; Gianmaria Miolo; Davide Lombardi; Simona Scalone; Simon Spazzapan; Samuele Massarut; Tiziana Perin; Riccardo Dolcetti; Agostino Steffan; Valli De Re
Journal:  Front Immunol       Date:  2022-01-12       Impact factor: 7.561

4.  KIR gene content in amerindians indicates influence of demographic factors.

Authors:  Danillo Gardenal Augusto; Bruno Zagonel Piovezan; Luiza Tamie Tsuneto; Sidia Maria Callegari-Jacques; Maria Luiza Petzl-Erler
Journal:  PLoS One       Date:  2013-02-25       Impact factor: 3.240

5.  Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy.

Authors:  Valli De Re; Laura Caggiari; Mariangela De Zorzi; Renato Talamini; Vito Racanelli; Mario D' Andrea; Angela Buonadonna; Vittorina Zagonel; Erika Cecchin; Federico Innocenti; Giuseppe Toffoli
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

6.  Role of KIR and CD16A genotypes in colorectal carcinoma genetic risk and clinical stage.

Authors:  Angelica Canossi; Anna Aureli; Tiziana Del Beato; Piero Rossi; Luana Franceschilli; Flavio De Sanctis; Pierpaolo Sileri; Nicola di Lorenzo; Oreste Buonomo; Davide Lauro; Adriano Venditti; Giuseppe Sconocchia
Journal:  J Transl Med       Date:  2016-08-12       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.